|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/15/23 Biogen Inc. 10-K 12/31/22 170:30M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.68M
3: EX-10.20 Material Contract HTML 58K
2: EX-10.3 Material Contract HTML 762K
4: EX-10.45 Material Contract HTML 922K
5: EX-10.46 Material Contract HTML 52K
6: EX-21 Subsidiaries List HTML 57K
7: EX-23 Consent of Expert or Counsel HTML 42K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 47K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 47K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 45K
16: R1 Cover Page HTML 106K
17: R2 Audit Information HTML 48K
18: R3 Consolidated Statements of Income HTML 143K
19: R4 Consolidated Statements of Comprehensive Income HTML 85K
20: R5 Consolidated Balance Sheets HTML 175K
21: R6 Consolidated Balance Sheets (Parenthetical) HTML 49K
22: R7 Consolidated Statements of Cash Flows HTML 170K
23: R8 Consolidated Statements of Equity HTML 163K
24: R9 Summary of Significant Accounting Policies HTML 148K
25: R10 Acquisitions HTML 46K
26: R11 Dispositions HTML 53K
27: R12 Restructuring HTML 57K
28: R13 Revenue HTML 207K
29: R14 Inventory HTML 61K
30: R15 Intangible Assets and Goodwill HTML 89K
31: R16 Fair Value Measurements HTML 157K
32: R17 Financial Instruments HTML 131K
33: R18 Derivative Instruments HTML 115K
34: R19 Property, Plant and Equipment HTML 62K
35: R20 Leases HTML 93K
36: R21 Indebtedness HTML 83K
37: R22 Equity HTML 147K
38: R23 Earnings per Share HTML 61K
39: R24 Share-Based Payments HTML 151K
40: R25 Income Taxes HTML 142K
41: R26 Other Consolidated Financial Statement Detail HTML 88K
42: R27 Collaborative and Other Relationships HTML 184K
43: R28 Investments in Variable Interest Entities HTML 54K
44: R29 Litigation HTML 60K
45: R30 Commitments and Contingencies HTML 55K
46: R31 Guarantees HTML 47K
47: R32 Employee Benefit Plans HTML 54K
48: R33 Segment Information HTML 96K
49: R34 Summary of Significant Accounting Policies HTML 213K
(Policies)
50: R35 Summary of Significant Accounting Policies HTML 48K
(Tables)
51: R36 Restructuring (Tables) HTML 51K
52: R37 Revenue (Tables) HTML 214K
53: R38 Inventory (Tables) HTML 58K
54: R39 Intangible Assets and Goodwill (Tables) HTML 81K
55: R40 Fair Value Measurements (Tables) HTML 148K
56: R41 Financial Instruments (Tables) HTML 131K
57: R42 Derivative Instruments (Tables) HTML 113K
58: R43 Property, Plant and Equipment (Tables) HTML 57K
59: R44 Leases (Tables) HTML 96K
60: R45 Indebtedness (Tables) HTML 67K
61: R46 Equity (Tables) HTML 138K
62: R47 Earnings per Share (Tables) HTML 59K
63: R48 Share-Based Payments (Tables) HTML 144K
64: R49 Income Taxes (Tables) HTML 128K
65: R50 Other Consolidated Financial Statement Detail HTML 90K
(Tables)
66: R51 Collaborative and Other Relationships (Tables) HTML 129K
67: R52 Segment Information (Tables) HTML 88K
68: R53 Summary of Significant Accounting Policies - HTML 76K
Narrative (Details)
69: R54 Summary of Significant Accounting Policies - HTML 58K
Summary of Property, Plant and Equipment Estimated
Useful Lives (Details)
70: R55 Acquisitions - (Details) HTML 47K
71: R56 Dispositions (Details) HTML 97K
72: R57 Restructuring - Additional Information (Details) HTML 59K
73: R58 Restructuring - Restructuring Reserve Roll Forward HTML 56K
(Details)
74: R59 Revenue - Revenues by Product (Details) HTML 131K
75: R60 Revenue - Narrative (Details) HTML 79K
76: R61 Revenue - Reserves for Discounts and Allowances HTML 67K
(Details)
77: R62 Revenue - Total Reserves for Discounts and HTML 50K
Allowances (Details)
78: R63 Revenue - Revenues from Anti-CD20 Therapeutic HTML 61K
Programs (Details)
79: R64 Revenue - Other Revenues (Details) HTML 58K
80: R65 Inventory - Components of Inventory (Details) HTML 58K
81: R66 Inventory - Narrative (Details) HTML 61K
82: R67 Intangible Assets and Goodwill - Summary of HTML 81K
Intangible Assets (Details)
83: R68 Intangible Assets and Goodwill - Narrative HTML 111K
(Details)
84: R69 Intangible Assets and Goodwill - Estimated Future HTML 54K
Amortization of Intangible Assets (Details)
85: R70 Intangible Assets and Goodwill - Changes in HTML 49K
Goodwill (Details)
86: R71 Fair Value Measurements - Summary of Assets and HTML 110K
Liabilities Recorded at Fair Value (Details)
87: R72 Fair Value Measurements - Summary of Significant HTML 56K
Unobservable Inputs (Details)
88: R73 Fair Value Measurements - Narrative (Details) HTML 89K
89: R74 Fair Value Measurements - Summary of Fair and HTML 66K
Carrying Value of Debt Instruments (Details)
90: R75 Fair Value Measurements - Fair Value of Contingent HTML 51K
Consideration Obligations (Details)
91: R76 Financial Instruments - Summary of Financial HTML 53K
Assets with Maturities (Details)
92: R77 Financial Instruments - Summary of Marketable HTML 88K
Securities (Details)
93: R78 Financial Instruments - Summary of Contractual HTML 65K
Maturities (Details)
94: R79 Financial Instruments - Narrative (Details) HTML 48K
95: R80 Financial Instruments - Proceeds from Marketable HTML 50K
Debt Securities (Details)
96: R81 Derivative Instruments - Narrative (Details) HTML 92K
97: R82 Derivative Instruments - Foreign Currency Forward HTML 54K
Contracts Entered into Hedge Forecasted Revenues
(Details)
98: R83 Derivative Instruments - Summary of Unrealized HTML 50K
Gain (Loss) on Derivative Instruments Included in
AOCI (Details)
99: R84 Derivative Instruments - Summary of the Effect of HTML 57K
Derivatives Designated as Cash Flow Hedging
Instruments (Details)
100: R85 Derivative Instruments - Summary of the Effect of HTML 54K
Derivatives Designated as Net Investment Hedging
Instruments (Details)
101: R86 Derivative Instruments - Summary of the Fair Value HTML 63K
for our Outstanding Derivatives (Details)
102: R87 Property, Plant and Equipment - Components of HTML 75K
property, plant, and equipment, net (Details)
103: R88 Property, Plant and Equipment - Narrative HTML 85K
(Details)
104: R89 Leases - Narrative (Details) HTML 67K
105: R90 Leases - Schedule of Operating Leases (Details) HTML 62K
106: R91 Leases - Operating Lease Costs (Details) HTML 56K
107: R92 Leases - Operating Lease Liability Maturity HTML 62K
(Details)
108: R93 Leases - Operating Lease Weighted Average HTML 47K
Remaining Term and Discount Rate (Details)
109: R94 Leases - Operating Lease Supplemental Cash Flow HTML 47K
Disclosure (Details)
110: R95 Indebtedness - Summary of Indebtedness (Details) HTML 70K
111: R96 Indebtedness - Exchange Offer (Details) HTML 69K
112: R97 Indebtedness - Additional Information (Details) HTML 112K
113: R98 Indebtedness - Total Debt Maturities (Details) HTML 69K
114: R99 Equity - Narrative (Details) HTML 76K
115: R100 Equity - Summary of Common Stock (Details) HTML 49K
116: R101 Equity - Accumulated Other Comprehensive Income HTML 82K
(Loss) (Details)
117: R102 Equity - Reclassification out of Accumulated Other HTML 88K
Comprehensive Income (Details)
118: R103 Earnings per Share - Basic and Diluted Earnings HTML 76K
Per Share (Details)
119: R104 Earnings per Share - Narrative (Details) HTML 44K
120: R105 Share-Based Payments - Share-based Compensation HTML 61K
Expense Included in Consolidation Statements of
Income (Details)
121: R106 Share-Based Payments - Summary of Share-based HTML 70K
Compensation Expense Associated with Each
Share-based Compensating Programs (Details)
122: R107 Share-Based Payments - Narrative (Details) HTML 128K
123: R108 Share-Based Payments - Tax Benefit and Cash HTML 47K
Received from Stock Option Exercises (Details)
124: R109 Share-Based Payments - Market Stock Units Activity HTML 68K
(Details)
125: R110 Share-Based Payments - Assumptions Used in HTML 64K
Valuation of Market Based Stock Units (Details)
126: R111 Share-Based Payments - Performance Stock Units HTML 67K
Settled in Stock Activity (Details)
127: R112 Share-Based Payments - Assumptions Used in HTML 63K
Valuation of Performance Shares (Details)
128: R113 Share-Based Payments - Performance Stock Units HTML 54K
Settled in Cash Activity (Details)
129: R114 Share-Based Payments - Time-Vested Restricted HTML 71K
Stock Units Activity (Details)
130: R115 Share-Based Payments - Shares Issued Under HTML 51K
Employee Stock Purchase Plan (Details)
131: R116 Income Taxes - Income Before Income Tax Provision HTML 82K
and the Income Tax Expense (Details)
132: R117 Income Taxes - Narrative (Details) HTML 123K
133: R118 Income Taxes - Components of Deferred Tax Assets HTML 80K
and Liabilities (Details)
134: R119 Income Taxes - Tax Rate (Details) HTML 74K
135: R120 Income Taxes - Accounting for Uncertainty in HTML 57K
Income Taxes (Details)
136: R121 Other Consolidated Financial Statement Detail - HTML 48K
Supplemental Cash Flow Information (Details)
137: R122 Other Consolidated Financial Statement Detail - HTML 68K
Other Income (Expense), Net (Details)
138: R123 Other Consolidated Financial Statement Detail - HTML 52K
Narrative (Details)
139: R124 Other Consolidated Financial Statement Detail - HTML 50K
Gain (Loss) on Investments (Details)
140: R125 Other Consolidated Financial Statement Detail - HTML 59K
Accrued Expense and Other (Details)
141: R126 Collaborative and Other Relationships - OCREVUS HTML 56K
(Details)
142: R127 Collaborative and Other Relationships - HTML 55K
Mosunetuzumab (Details)
143: R128 Collaborative and Other Relationships - HTML 50K
Co-promotion Profit Sharing Formula (Details)
144: R129 Collaborative and Other Relationships - Profit HTML 63K
Sharing (Details)
145: R130 Collaborative and Other Relationships - Pretax HTML 48K
Profit Sharing Formula (Details)
146: R131 Collaborative and Other Relationships - Revenues HTML 60K
from Anti-CD20 Therapeutic Programs (Details)
147: R132 Collaborative and Other Relationships - Ionis HTML 105K
(Details)
148: R133 Collaborative and Other Relationships - Eisai HTML 53K
(Details)
149: R134 Collaborative and Other Relationships - Summary of HTML 53K
Activity Related to BAN2401 and Elenbecestat
Collaboration (Details)
150: R135 Collaborative and Other Relationships - ADUHELM HTML 84K
Collaboration Agreement (Details)
151: R136 Collaborative and Other Relationships - Summary of HTML 61K
Activity Related to Aducanumab Collaboration
(Details)
152: R137 Collaborative and Other Relationships - Summary of HTML 49K
Activity Related to the UCB Collaboration
(Details)
153: R138 Collaborative and Other Relationships - Alkermes HTML 57K
(Details)
154: R139 Collaborative and Other Relationships - Acorda HTML 50K
(Details)
155: R140 Collaborative and Other Relationships - Other HTML 97K
Arrangements (Details)
156: R141 Collaborative and Other Relationships - Summary of HTML 52K
Activity Related to Sage Therapeutics (Details)
157: R142 Collaborative and Other Relationships - Summary of HTML 49K
Activity Related To Denali Therapeutics (Details)
158: R143 Collaborative and Other Relationships - Summary of HTML 49K
Activity Related to Sangamo Therapeutics (Details)
159: R144 Collaborative and Other Relationships - Samsung HTML 169K
Bioepis (Details)
160: R145 Investments in Variable Interest Entities HTML 73K
(Details)
161: R146 Litigation (Details) HTML 45K
162: R147 Commitments and Contingencies (Details) HTML 101K
163: R148 Employee Benefit Plans (Details) HTML 70K
164: R149 Segment Information - Narrative (Details) HTML 49K
165: R150 Segment Information - Geographic Information HTML 88K
(Details)
168: XML IDEA XML File -- Filing Summary XML 330K
166: XML XBRL Instance -- biib-20221231_htm XML 6.24M
167: EXCEL IDEA Workbook of Financial Reports XLSX 288K
12: EX-101.CAL XBRL Calculations -- biib-20221231_cal XML 360K
13: EX-101.DEF XBRL Definitions -- biib-20221231_def XML 2.10M
14: EX-101.LAB XBRL Labels -- biib-20221231_lab XML 3.43M
15: EX-101.PRE XBRL Presentations -- biib-20221231_pre XML 2.64M
11: EX-101.SCH XBRL Schema -- biib-20221231 XSD 428K
169: JSON XBRL Instance as JSON Data -- MetaLinks 835± 1.26M
170: ZIP XBRL Zipped Folder -- 0000875045-23-000009-xbrl Zip 2.51M
 | Download this zipped .zip folder |
| Files: | biib-20221231.htm biib-20221231.xsd biib-20221231_cal.xml biib-20221231_def.xml biib-20221231_g1.jpg biib-20221231_g10.jpg biib-20221231_g11.jpg biib-20221231_g12.jpg biib-20221231_g13.jpg biib-20221231_g14.jpg biib-20221231_g15.jpg biib-20221231_g16.jpg biib-20221231_g17.jpg biib-20221231_g18.jpg biib-20221231_g19.jpg biib-20221231_g2.jpg biib-20221231_g20.jpg biib-20221231_g21.jpg biib-20221231_g22.jpg biib-20221231_g23.jpg biib-20221231_g24.jpg biib-20221231_g25.jpg biib-20221231_g26.jpg biib-20221231_g27.jpg biib-20221231_g28.jpg biib-20221231_g29.jpg biib-20221231_g3.jpg biib-20221231_g30.jpg biib-20221231_g31.jpg biib-20221231_g32.jpg biib-20221231_g33.jpg biib-20221231_g34.jpg biib-20221231_g35.jpg biib-20221231_g36.jpg biib-20221231_g37.jpg biib-20221231_g38.jpg biib-20221231_g39.jpg biib-20221231_g4.jpg biib-20221231_g40.jpg biib-20221231_g41.jpg biib-20221231_g42.jpg biib-20221231_g43.jpg biib-20221231_g5.jpg biib-20221231_g6.jpg biib-20221231_g7.jpg biib-20221231_g8.jpg biib-20221231_g9.jpg biib-20221231_lab.xml biib-20221231_pre.xml biib-20221231xex21.htm biib-20221231xex23.htm biib-20221231xex311.htm biib-20221231xex312.htm biib-20221231xex321.htm exhibit103amendmenttocredi.htm exhibit1045amendedandresta.htm exhibit1046firstamendmentt.htm exhibit10ormofnonqualified.htm |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/14/24 Biogen Inc. 10-K 12/31/23 176:24M |